Loading...
| Name | Option type | Quality (1-5)↓ | Topics | Created | |
|---|---|---|---|---|---|
Imdelltra reduces mortality rate for ES-SCLC by May 2024  | Binary | 5 | 7 months ago | ||
Severe side effects lead to Imdelltra discontinuation by end of 2024 | Binary | 5 | 7 months ago | ||
Imdelltra approved for other cancer types by end of 2024 | Binary | 5 | 7 months ago | ||
Global adoption of Imdelltra as standard treatment by end of 2024 | Categorical | 5 | 7 months ago | ||
Financial impact from Imdelltra sales in 2024 | Categorical | 5 | 7 months ago | ||
Amgen stock performance following Imdelltra success by end of 2024 | Categorical | 4 | 7 months ago |